ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1377

Decoy Receptor 3 Regulates the Expression of Tryptophan Hydroxylase TPH1 in Rheumatoid Synovial Fibroblasts

Toshihisa Maeda1, Yasushi Miura2, Koji Fukuda3, Shinya Hayashi4 and Masahiro Kurosaka1, 1Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, 2Department of Rehabilitation Science, Graduate School of Health Sciences, Kobe University, Kobe, Japan, 3Dept. of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, 4Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: bone metabolism, inflammatory cytokines, osteoarthritis and rheumatoid arthritis, synovium

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Tryptophan hydroxylase (TPH) which catalyzes the hydroxylation of L-tryptophan is the rate-limiting enzyme involved in the synthesis of serotonin. TPH has two isoforms; TPH1 expresses in peripheral and central nerve system (CNS) tissues expressing serotonin, such as skin, intestine, and pineal gland, while TPH2 expresses exclusively and dominantly in CNS. Recently several studies suggested that serotonergic systems play an important role in modulating inflammatory pain and bone remodeling. We previously reported that decoy receptor 3 (DcR3), a member of TNF receptor superfamily, overexpressed in rheumatoid synovial fibroblasts (RA-FLS) stimulated with TNFα inhibits Fas-induced apoptosis. We recently reported that DcR3 induced VLA-4 expression in THP-1 macrophages to inhibit cycloheximide-induced apoptosis, and that DcR3 inhibited cell proliferation induced by TNFα or IL-1β via TL1A expressed on RA-FLS. We also reported that the concentration of DcR3 in sera and joint fluids of patients with RA was significantly higher than those with osteoarthritis (OA).

Further, by using comprehensive genetic analysis using microarrays, we newly identified TPH1 as one of the genes of which expression in RA-FLS was suppressed by DcR3.

Therefore, in this study, we investigated the expression of TPH1 in RA and OA-FLS stimulated with DcR3 and inflammatory cytokines to elucidate the involvement of TPH1 and DcR3 in the pathogenesis of RA.

Methods:

Real-time polymerase chain reaction (real-time PCR). Primary cultured RA or OA-FLS were incubated with 1.0 µg/ml recombinant human DcR3-Fc protein or 1.0 µg/ml control IgG1 for 12 hours, or 1.0 ng/ml recombinant human TNFα or 1.0 ng/ml IL-1β for 24 hours, then the relative expression levels of TPH1 mRNA were quantified by real-time PCR.

Immunohistochemistry. Serotonin expressed in rheumatoid synovial tissues was detected by immunohistochemistry.

Results:

TPH1 mRNA was expressed in both RA and OA-FLS. TPH1 mRNA expression was decreased significantly by DcR3 in RA-FLS, but not in OA-FLS. Meanwhile, TPH1 mRNA expression was significantly decreased by TNFα or IL-1β both in RA and OA-FLS. Immunohistochemistry confirmed that serotonin was present in multi-layered synovial lining cells.

Conclusion:

In this study, we first revealed that TPH1 in RA-FLS was suppressed by DcR3 in a disease-specific fashion. Therefore, TPH1 in RA-FLS regulated by DcR3 may affect serotonin expression to be involved in the pathogenesis of RA, such as modulating inflammatory pain and bone remodeling. Both DcR3 and TPH1 could be a possible therapeutic target of RA.


Disclosure:

T. Maeda,
None;

Y. Miura,
None;

K. Fukuda,
None;

S. Hayashi,
None;

M. Kurosaka,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/decoy-receptor-3-regulates-the-expression-of-tryptophan-hydroxylase-tph1-in-rheumatoid-synovial-fibroblasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology